SOURCES SOUGHT
B -- : Project and study support for Surveillance for Emerging Infectious Disease and Clinical Trials in Cambodia for the Armed Forces Research Institute of Medical Sciences (AFRIMS).
- Notice Date
- 1/24/2018
- Notice Type
- Sources Sought
- NAICS
- 541715
— Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Contracting Office
- Department of the Army, U.S. Army Medical Research Acquisition Activity, U.S. Army Medical Research Acquisition Activity, Attn: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014, Maryland, 21702-5014, United States
- ZIP Code
- 21702-5014
- Solicitation Number
- W81XWH-18-Q-CAMBODIA
- Point of Contact
- Flodean Billings, Phone: 3016192648
- E-Mail Address
-
flodean.p.billings.civ@mail.mil
(flodean.p.billings.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- Title: Project and study support for Surveillance for Emerging Infectious Disease and Clinical Trials in Cambodia for the Armed Forces Research Institute of Medical Sciences (AFRIMS). Solicitation: W81XWH-18-Q-CAMBODIA Notice Type: Request for Information (RFI) Response Date: 30 January 2018 NAICS: 541- Professional, Scientific, and Technical Services 541715-Research and Development in the Physical, Engineering and Life Sciences (except Nanotechnology) Scope: The Government requires support to Procurement support, provision of clinical and epidemiological services, purchase of supplies and equipment, transportation, communications and administrative support. Objectives: The objective is to provide procurement support for AFRIMS research projects involving surveillance for emerging infectious diseases and conduct of clinical trials within Cambodia. Pathogens that may be the subject of disease surveillance studies include respiratory viral pathogens, leptospirosis, bacterial pathogens, agents of parasitic disease including malaria, and other emerging infections. Products that may be evaluated in clinical trials include anti-malarial drugs and/or vaccines, anti-viral drugs, anti-microbial drugs, and other potential candidates with activity against infectious disease agents. In addition, the contractor must provide office space, utilities, as well as security per the regulations of the United States Embassy Security Office. RFI INSTRUCTIONS: Interested parties are asked to respond to this RFI and submit a capabilities statement that supports the focus of this RFI. Please review the place of performance requirements. Please submit written responses via email in Microsoft Office 2000 or 2007 format. All responses should be complete: in 12-point font; and not to exceed 5 pages total, including graphics, tables, and appendices. No hardcopies shall be accepted. No written solicitation document is available at this time. Telephone requests will not be honored, and no bidders list shall be maintained. No inquiries regarding any potential future acquisition activities shall be entertained. There is proprietary information involved in this requirement which may preclude some established clinical trial centers from competing on this requirement, although no decisions have been finalized at this time. Potential offerors are requested to direct all questions via email to the Point of Contact listed below. Responses are due to the Point of Contact, Ms. Flodean Billings at email: flodean.p.billings.civ@mail.mil no later than 9:00AM EST, Tuesday, January 30 2018. CAUTION: This is an active requirement. Contractors are strictly prohibited from discussing this requirement with any member of the program office. All discussion shall be with the point of contact listed above. DISCLAIMER: This RFI is issued solely for information and planning purposes and does not constitute a solicitation. Neither unsolicited proposals nor any kinds of offers will be considered in response to this RFI. Responses to this notice are not offers and will not be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. All information received in response to this RFI that is marked proprietary will be handled accordingly. Responses to the RFI will not be returned.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/W81XWH-18-Q-CAMBODIA/listing.html)
- Place of Performance
- Address: Armed Forces Research Institute of Medical Sciences (AFRIMS)., Cambodia
- Record
- SN04798569-W 20180126/180124231458-b3473e86ed1e7091d1636bdf255dc44e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |